Novo Nordisk mostly unaffected by COVID-19 in Q1

Novo Nordisk is with the exception of the postponement of new clinical trials mostly unaffected by COVID-19. Sales in Q1 were however positively affected by stock piling of insulin. Growth continues to be spearheaded by Ozempic┬«, whereas Victoza┬« and Levemir┬« in the US continue to lead the decline. Rybelsus┬« revenue totaled DKKb 229 in the …